Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Amer H. Zureikat"'
Autor:
Herbert J. Zeh, Shikhar Uttam, Alessandro Paniccia, Melissa E. Hogg, Kevin McGrath, Adam Slivka, Vikram C. Gorantla, Rohit Das, Katelyn Smith, Roby Antony Thomas, Asif Khalid, Michael S. Landau, Kenneth E. Fasanella, Natalie Seiser, James F. Pingpank, Harkirat Singh, Nathan Bahary, Patrick Henn, Kenneth K. Lee, Brian K. Theisen, Melanie Ongchin, Savreet Sarkaria, Randall E. Brand, Aatur D. Singhi, Brian A. Boone, Amer H. Zureikat, Susannah G. Ellsworth, N. Paul Ohori, Anil K. Dasyam, Jennifer Chennat, Susan Shyu, John C. Rhee
Publikováno v:
Clin Gastroenterol Hepatol
BACKGROUND & AIMS: The assessment of therapeutic response after neoadjuvant treatment and pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) has been an ongoing challenge. Several limitations have been encountered when employing current gradi
Autor:
Nathan Bahary, Naomi Fei, Rajesh Ramanathan, Melissa E. Hogg, Sijin Wen, Brian A. Boone, Herbert J. Zeh, Amer H. Zureikat, Aatur D. Singhi, Michael T. Lotze
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1822-1829 (2021)
Clinical and Translational Science
Clinical and Translational Science
SMAD4, a tumor suppressor gene, is lost in up to 60%–90% of pancreatic adenocarcinomas (PDAs). Loss of SMAD4 allows tumor progression by upregulating autophagy, a cell survival mechanism that counteracts apoptosis and allows intracellular recycling
Autor:
Alessandro Paniccia, Nathan Bahary, David L Bartlett, Kenneth K. Lee, Kenneth J. Smith, Amer H. Zureikat, Caroline J. Rieser, Sowmya Narayanan
Publikováno v:
J Surg Oncol
INTRODUCTION: Neoadjuvant therapy (NAT) is an emerging strategy for operable pancreatic ductal adenocarcinoma (PDAC). While neoadjuvant therapy increases multimodal therapy completion, it risks functional decline and treatment drop out. We used decis
Autor:
Asif Khalid, Nathan Bahary, Sharon Winters, Lauren Stitt, Adam C. Olson, Richard S. Hoehn, Adam Slivka, Kenneth K. Lee, Ritu Sarkaria, James Ohr, Caroline J. Rieser, Randal E. Brand, Steve Burton, Vikram C. Gorantla, David L. Bartlett, Kenneth E. Fasanella, Jennifer Chennat, Rohit Das, Aatur D. Singhi, Herbert J. Zeh, Anuradha Krishnamurthy, Melissa E. Hogg, John C. Rhee, Susannah G. Ellsworth, Kevin McGrath, Alessandro Paniccia, Amer H. Zureikat
Publikováno v:
Ann Surg Oncol
AIMS: National studies have demonstrated disparities in the treatment and survival of pancreatic cancer patients based on socioeconomic status (SES). This study aimed to identify specific differences in perioperative management and outcomes based on
Autor:
Amer H. Zureikat, Daniel Barnett, Ying Huang, Mirna Kheir Gouda, Luke Wisniewski, Douglas B. Evans, Ben Staal, Chong-Feng Gao, Peter J. Allen, Dennis Plenker, Aatur D. Singhi, Randall E. Brand, Ying Liu, David A. Tuveson, Susan Tsai, Ian Beddows, Mohammed Aldakkak, Brian B. Haab, Johnathan Hall, Richard R. Drake
Publikováno v:
Clin Cancer Res
Purpose:A subset of pancreatic ductal adenocarcinomas (PDACs) is highly resistant to systemic chemotherapy, but no markers are available in clinical settings to identify this subset. We hypothesized that a glycan biomarker for PDACs called sialylated
Autor:
Rohit Das, Savreet Sarkaria, Randall E. Brand, Alessandro Paniccia, Samer AlMasri, Kenneth E. Fasanella, Melissa E. Hogg, Anil K. Dasyam, Jennifer Chennat, Asif Khalid, Kenneth K. Lee, Adam Slivka, Herbert J. Zeh, Mazen S. Zenati, Amer H. Zureikat, David L. Bartlett, Aatur D. Singhi, Kevin McGrath
Publikováno v:
Annals of Surgery. 275:e789-e795
OBJECTIVE To evaluate the significance of UDD in IPMNs. BACKGROUND The uncinate process of the pancreas has an independent ductal drainage system. International consensus guidelines of IPMNs still consider it as a branch-duct, even though it is the m
Autor:
A. Floortje van Oosten, Michael J. Pflüger, Wenjie Huang, Elizabeth D. Thompson, Vincent P. Groot, Steven Gallinger, Sandra Fischer, Limin Xia, Neil M. Neumann, Nicholas J. Roberts, Richard A. Burkhart, Stefan Heinrich, Alina Hasanain, Claudio Luchini, Jin He, Kim-Vy Nguyen-Ngoc, Bernat Navarro-Serer, Anne Macgregor-Das, Laura D. Wood, Maria A. Trujillo, Gemma Lionheart, Andrew J. Ewald, Peter Chianchiano, Michael Goggins, Amer H. Zureikat, Christopher L. Wolfgang, Randall E. Brand, Yea Ji Jeong, Matthias M. Gaida, Cameron Dowiak, Tammy Ng, Aatur D. Singhi, Danielle Jones, Kohei Fujikura, Bo Huang, Nicola Veronese
Publikováno v:
Cancer Res
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by extensive local invasion and systemic spread. In this study, we employed a three-dimensional organoid model of human pancreatic cancer to characterize the molecular
Autor:
Quisette P. Janssen, Jacob L. van Dam, Laura R. Prakash, Deesje Doppenberg, Christopher H. Crane, Casper H.J. van Eijck, Susannah G. Ellsworth, William R. Jarnagin, Eileen M. O’Reilly, Alessandro Paniccia, Marsha Reyngold, Marc G. Besselink, Matthew H.G. Katz, Ching-Wei D. Tzeng, Amer H. Zureikat, Bas Groot Koerkamp, Alice C. Wei
Publikováno v:
Journal of the National Comprehensive Cancer Network, 20(7), 783-791. Cold Spring Publishing LLC
Journal of the National Comprehensive Cancer Network : JNCCN, 20(7), 783-791. Cold Spring Publishing LLC
J Natl Compr Canc Netw
Journal of the National Comprehensive Cancer Network : JNCCN, 20(7), 783-791. Cold Spring Publishing LLC
J Natl Compr Canc Netw
Background: The value of neoadjuvant radiotherapy (RT) after 5-fluorouracil with leucovorin, oxaliplatin, and irinotecan, with or without dose modifications [(m)FOLFIRINOX], for patients with borderline resectable (BR) pancreatic ductal adenocarcinom
Autor:
Caroline J. Rieser, David L. Bartlett, Asmita Chopra, Kenneth K.W. Lee, Sowmya Narayanan, Amer H. Zureikat, Alessandro Paniccia, Samer AlMasri, Tracy Daum, Mazen S. Zenati, Katelyn Smith, Nathan Bahary, Vivianne Oyefusi, Ibrahim Nassour
Publikováno v:
J Surg Oncol
BACKGROUND AND OBJECTIVES Neoadjuvant chemotherapy (NAT) for pancreatic adenocarcinoma (PDAC) is increasingly being utilized. However, a significant number of patients will experience early recurrence, possibly negating the benefit of surgery. We aim
Autor:
Amer H. Zureikat, David L Bartlett, Kenneth K. Lee, Mazen S. Zenati, Nathan Bahary, Alessandro Paniccia, Caroline J. Rieser, Sowmya Narayanan
Publikováno v:
Ann Surg Oncol
Neoadjuvant therapy (NAT) is a growing strategy for patients with resectable pancreatic ductal adenocarcinoma (PDAC). Elderly patients are at increased risk of treatment withdrawal due to functional decline, and the benefit of NAT in this cohort rema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3263486cc36ea0870e151d9eee750612
https://europepmc.org/articles/PMC8614241/
https://europepmc.org/articles/PMC8614241/